China SXT Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-6.2M | $-3.3M | $-3.1M | $-5.9M | $-5.7M | $-2.7M | $-10.3M | $1.5M |
| Depreciation & Amortization | $73.7K | $82.3K | $203.2K | $250.2K | $320.0K | $345.4K | $331.8K | $180.9K |
| Depreciation | $67.8K | $75.1K | $195.8K | $242.2K | $337.4K | $337.4K | $323.9K | $174.0K |
| Amortization | $5.8K | $7.2K | $7.5K | $7.9K | $8.5K | $8.0K | $8.0K | $7.0K |
| Stock-Based Compensation | $5.3M | — | $352.1K | $554.6K | $2.3M | — | — | — |
| Net Cash from Operating Activities | $-4.0M | $-2.3M | $-1.9M | $-80.8K | $268.3K | $-1.3M | $934.2K | $239.2K |
| Investing Activities | ||||||||
| Capital Expenditures | — | $2.0K | $7.1K | — | $60.9K | $78.3K | $130.8K | $535.8K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.3M | $63.5K | $26.4K | $-12.3K | $-46.9K | $-5.8M | $-5.5M | $-610.1K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $14.4M | $8.4M | $-2.6M | $2.9M | $1.6M | $12.4M | $3.0M | $9.0M |
| Net Change in Cash | $10.0M | $6.1M | $-5.3M | $1.8M | $2.2M | $6.1M | $-2.0M | $8.6M |
| Free Cash Flow | — | $-2.3M | $-1.9M | — | $207.4K | $-1.4M | $803.4K | $-296.6K |